Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

Video

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Georg Lenz, MD, professor, Hematology and Oncology, Department of Medicine, Universitätsklinikum Münster, Lenz Lab: Translational Oncology, discussed the European approval of lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-cell lymphoma.

The European approval of liso-cel in April 2022 was based on long-term follow-up data from the phase 1 TRANSCEND-NHL-001 trial (NCT02631044). In February 2021, the FDA approved liso-cel for the treatment of adult patients with certain types of LBCL who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

Liso-cel has proved efficacious for heavily pretreated patients that are generally characterized by poor outcome, Lenz explains. Liso-cel has shown to be curative in a significant proportion of patients, and the treatment has been well tolerated, with a low rate of neurologic events, Lenz adds.

Prior to the European approval of liso-cel, the CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) received European approval, and both are curative and tolerable treatment options, Lenz continues. However, based on the TRANSCEND-NHL-001 data, liso-cel could challenge these previously approved therapies, Lenz concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine